← Back to Screener
Annovis Bio, Inc. (ANVS)
Price$1.82
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-66.45%
Price vs S&P 500 (4W)-8.97%
VGM Score19.66
Market Capitalization$66.52M
All Metrics
Book Value / Share (Quarterly)$0.11
P/TBV (Annual)2.36x
Cash Flow / Share (Quarterly)$-0.93
Price vs S&P 500 (YTD)-55.44%
EPS (TTM)$-1.70
10-Day Avg Trading Volume1.53M
EPS Excl Extra (TTM)$-1.70
EPS (Annual)$-1.40
ROI (Annual)-171.23%
Cash / Share (Quarterly)$0.50
ROA (Last FY)-136.87%
EBITD / Share (TTM)$-1.79
ROE (5Y Avg)-125.97%
Cash Flow / Share (Annual)$-0.94
P/B Ratio21.28x
P/B Ratio (Quarterly)20.23x
Net Income / Employee (Annual)$-3,606,800
Net Interest Coverage (TTM)-7.25x
ROA (TTM)-215.48%
EPS Incl Extra (Annual)$-1.40
Current Ratio (Annual)5.80x
Quick Ratio (Quarterly)1.11x
3-Month Avg Trading Volume0.82M
52-Week Price Return-20.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.74
52-Week High$5.50
EPS Excl Extra (Annual)$-1.40
26-Week Price Return-50.52%
Quick Ratio (Annual)5.37x
13-Week Price Return-30.69%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.27x
Enterprise Value$52.30M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.72
3-Month Return Std Dev98.59%
Net Income / Employee (TTM)$-5,115,400
ROE (Last FY)-171.23%
Net Interest Coverage (Annual)-0.89x
EPS Basic Excl Extra (Annual)$-1.40
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.70
ROI (TTM)-318.08%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.47
Price vs S&P 500 (52W)-48.21%
Year-to-Date Return-44.51%
5-Day Price Return-13.90%
EPS Normalized (Annual)$-1.40
ROA (5Y Avg)-193.17%
Month-to-Date Return-2.54%
Cash Flow / Share (TTM)$-1.72
EBITD / Share (Annual)$-1.44
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-125.97%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.70
P/TBV (Quarterly)10.02x
P/B Ratio (Annual)5.44x
Book Value / Share (Annual)$0.62
Price vs S&P 500 (13W)-40.43%
Beta1.16x
Revenue / Share (TTM)$0.00
ROE (TTM)-318.08%
52-Week Low$1.54
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-0.63est. -0.40
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANVSAnnovis Bio, Inc. | — | — | F | $1.82 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Annovis Bio is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases, primarily Alzheimer's and Parkinson's disease. Its pipeline includes Buntanetap for chronic neurodegeneration, ANVS405 for acute neurodegeneration, and ANVS301 for Alzheimer's disease.